FOR IMMEDIATE RELEASE
MESA, Ariz. — January 1, 2026
We’re thrilled to announce the publication of a groundbreaking systematic review and meta-analysis led by Dr. Greg Marchand and the dedicated research team at the Marchand Institute for Minimally Invasive Surgery!
Titled “Laparoendoscopic Single-Site Surgery Versus Conventional Laparoscopic Surgery in Ovarian Cystectomy: A Meta-Analysis”, this comprehensive study compares two advanced minimally invasive techniques for removing benign ovarian cysts — Laparoendoscopic Single-Site Surgery (LESS) (using a single small incision, often hidden at the umbilicus for superior cosmetic results) and Conventional Laparoscopic Surgery (CLS) (using multiple small incisions).
Analyzing data from 9 studies involving 1,368 women, the meta-analysis reveals compelling insights:
- LESS is associated with longer operative times (by about 9.4 minutes on average), likely due to the technical demands of working through a single port.
- However, patients undergoing LESS benefit from a shorter hospital stay (reduced by approximately 0.26 days).
- Importantly, there are no significant differences in key safety outcomes: postoperative pain scores (at 6 and 24 hours), estimated blood loss, need for opioid analgesics, drop in hemoglobin levels, or overall complication rates.
These findings strengthen the evidence that LESS is a safe, effective, and viable alternative to conventional laparoscopy for women with benign ovarian cysts — offering faster recovery and excellent cosmetic advantages while maintaining comparable safety and pain profiles.
This work adds valuable high-level evidence to the field of minimally invasive gynecologic surgery and reflects the Marchand Institute’s ongoing commitment to advancing women’s health through rigorous, volunteer-driven research.
Read the full open-access paper for free today:
- PubMed Central (PMC) (recommended – full text & PDF): https://pmc.ncbi.nlm.nih.gov/articles/PMC12734174/
- Direct PDF download: https://pmc.ncbi.nlm.nih.gov/articles/PMC12734174/pdf/jcm-14-08739.pdf
- Published in Journal of Clinical Medicine (December 10, 2025) – DOI: 10.3390/jcm14248739
We invite clinicians, researchers, and patients interested in the latest advancements in minimally invasive surgery to explore this important contribution. A huge thank you to our incredible team of researchers, students, and collaborators who made this possible — all volunteer efforts dedicated to improving outcomes for women everywhere!
Visit us at marchandinstitute.org to learn more about our ongoing research, educational programs, and mission to push the boundaries of minimally invasive techniques.
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###